Cargando…
Loading, please waitCargando…
Loading, please waitCondition × Stem Cells
A physician-led look at where mesenchymal stem cell (MSC) therapy stands for type 2 diabetes: what the published randomized evidence actually shows for glycemic control and insulin needs, who qualifies and who does not, and how care is delivered under COFEPRIS regulation at our clinic in Cancún, México. No prices are published online — every case is reviewed in a free medical evaluation, then quoted in writing, and always co-managed with your endocrinologist or primary-care physician.
TL;DR
Mesenchymal stem cell (MSC) therapy is an investigational, physician-led adjunct option for type 2 diabetes that — in published randomized and meta-analytic data — has been associated with lower HbA1c, lower daily insulin requirements, and improved markers of insulin resistance versus placebo at follow-up windows of up to 48 weeks. It is not a cure, not a replacement for guideline-directed care (lifestyle, metformin, GLP-1 / SGLT2, insulin where indicated), and not approved by major regulators for diabetes. At Regeneris Therapy in Cancún, México, every case starts with a free medical evaluation, is co-managed with your endocrinologist, and only then receives a personalized written quote.
The condition
Type 2 diabetes (T2D) is a chronic metabolic disease defined by chronically elevated blood glucose driven by two interacting problems: insulin resistance in peripheral tissues (muscle, liver, adipose) and a progressive decline in pancreatic β-cell function. It is the most common form of diabetes worldwide, accounting for the great majority of diagnosed cases, and it is increasingly common in México — including in adults seen at our clinic in Cancún. Beyond a number on a lab report, T2D drives microvascular and macrovascular complications (retinopathy, nephropathy, neuropathy, coronary disease, peripheral vascular disease) that accumulate over years of suboptimal control.
What the research shows
Peer-reviewed clinical evidence for MSC therapy in type 2 diabetes is more mature than in many regenerative indications — there are now multiple randomized controlled trials, dedicated literature reviews, and meta-analyses — but it is still classified as investigational. The signal is consistent enough to take seriously, and conservative enough to never overpromise. The notes below summarize the strongest sources we cite and what each does and does not show. None of it guarantees an individual outcome, and none of it substitutes for the care of your endocrinologist or primary-care physician.
A single-center, double-blinded, randomized, placebo-controlled phase II trial enrolled 91 Chinese adults with type 2 diabetes and randomized them to three intravenous infusions of umbilical cord-derived mesenchymal stem cells (UC-MSC) or placebo at 4-week intervals, with 48 weeks of follow-up. At 48 weeks, 20% of UC-MSC patients met the composite primary endpoint of HbA1c < 7.0% with a ≥ 50% reduction in daily insulin dose, versus 4.55% of placebo (statistically significant). The trial framed UC-MSC as a tolerable, biologically plausible adjunct — not a stand-alone replacement for standard care.
A meta-analysis of 13 clinical studies of MSC-based therapy in diabetes (302 subjects total, T1D and T2D combined) reported that the MSC-treated group had a significantly lower HbA1c at last follow-up compared with baseline, and that insulin requirements decreased significantly, without serious adverse events identified across the included studies. The authors framed MSC therapy as a possible adjunctive treatment for diabetes whose definitive role still depends on larger trials.
A systematic review and meta-analysis of 13 randomized controlled trials (507 participants total, with 308 living with type 2 diabetes) reported that, at 12-month follow-up versus placebo, MSC therapy was associated with significantly lower postprandial blood glucose and a significantly lower daily insulin dose requirement in T2D patients. No serious adverse events or mortality were reported during treatment and follow-up across the included studies; the most common events were mild, self-limiting hypoglycemia and minor procedure-related issues — supporting MSC as a generally tolerable adjunct, while the field still calls for larger, longer randomized trials.
A comprehensive review out of the UCSF Diabetes Center surveyed the stem cell trial landscape for diabetes mellitus and concluded that MSC-based therapies show 'constant and robust efficacy' for T2D patients across multiple trials, while their effectiveness in T1D remains more questionable. The authors are explicit that MSC therapy for diabetes is not yet an approved therapy and that the trial pipeline is still maturing — context that should anchor any honest patient conversation about regenerative options for T2D in Cancún, México.
Mechanistic context that frames the T2D literature. The field's founding figure reframed MSCs as 'medicinal signaling cells,' arguing their therapeutic benefit comes chiefly from secreted paracrine factors — exosomes, growth factors, cytokines — that modulate inflammation and tissue environments rather than from engraftment and direct tissue replacement. This is the underlying mechanism most often invoked to explain how an intravenous MSC infusion can plausibly influence systemic insulin sensitivity and β-cell stress without literally rebuilding the pancreas.
Read together, the literature supports a careful, conservative position: MSC therapy is biologically rational for type 2 diabetes, has shown a real signal in randomized and meta-analytic data, and is generally well tolerated — but it remains investigational and is not a substitute for guideline-directed diabetes care. Whether it is right for your specific case is a medical question, confirmed only in evaluation alongside your endocrinologist, never assumed from a search query.
Candidacy
MSC therapy for type 2 diabetes is not a first-line treatment and not a fit for every patient. The lists below describe the general clinical factors that point toward or away from regenerative care for this condition at our clinic in Cancún, México. None of these supersede a physician evaluation — they orient you before one. Every candidate is co-managed with their treating endocrinologist or primary-care physician throughout.
Regulation & location
Regeneris Therapy operates as a physician-led regenerative-medicine clinic in Cancún, Quintana Roo, México, under COFEPRIS — México's federal health authority, the regulatory equivalent of the U.S. FDA. That framework defines who may prescribe and deliver stem cell therapy, where cells may be processed, and what advertising claims a clinic may publish. For a chronic systemic disease like type 2 diabetes, that physician-led, federally regulated framing matters: care should never be a transactional purchase.
Our clinic operates under COFEPRIS Aviso Sanitario 2323025036X00098 and Aviso de Publicidad 2323022002A00053, the federal records that authorize medical operations and regulate any advertising of regenerative therapies in México.
Cells used in our protocols are expanded under sterile, COFEPRIS-certified laboratory conditions with donor screening and quality-control testing — a baseline patients and families should expect from any serious clinic in México.
Every protocol is prescribed and supervised by a licensed Mexican physician at our clinic in Cancún, México, and every T2D case is coordinated with the patient's endocrinologist or primary-care physician — never delivered in a clinical vacuum.
Patients traveling to Cancún, México from the United States, Canada, or elsewhere often combine evaluation, treatment, and rest on a single short itinerary; our team helps coordinate the medical side — including the hand-off to your home-country diabetes team — from your first message.
How we work
Our model is intentionally medical, not transactional. We do not publish prices online for stem cell therapy, and we do not sell a fixed package. Every type 2 diabetes case starts with a structured physician evaluation, is co-managed with your endocrinologist, and ends with a written plan and a personalized quote — so you can make an informed decision before committing.
Share your goals, recent HbA1c and full glucose panel, lipid and kidney function, current medications (including insulin, metformin, GLP-1 / SGLT2 / DPP-4), endocrinology notes, and any complications. A Regeneris physician reviews your case — by message or video first if you are traveling from outside Cancún — and answers honestly whether MSC therapy is worth considering as an adjunct.
We loop in your treating endocrinologist or primary-care physician. T2D is a chronic disease — any adjunct must fit alongside your existing care, not replace it. We will not proceed if that coordination is missing.
If MSC therapy is appropriate, you receive a written plan describing cell source, route of administration (typically intravenous infusion), number of sessions, follow-up schedule, and the personalized quote — clearly stated, no surprises. You take the document home and decide on your own time.
If you proceed, treatment is delivered at our clinic in Cancún, México under physician supervision, with structured follow-up that tracks HbA1c, insulin requirements, and symptoms. We reassess outcomes honestly — including the option to discontinue if MSC is not adding value alongside your standard diabetes care.
This is the same workflow whether you are a Cancún resident, a Mexican patient from another state, or an international patient flying in: free evaluation first, endocrinology coordination always, written quote only after we understand your case.
Honest expectations
We treat this section as the most important on the page. Marketing language in regenerative medicine has historically run ahead of the evidence; we are deliberately conservative because honesty is the only defensible position in a YMYL medical field — especially in a chronic disease like type 2 diabetes.
FAQ
The questions patients ask us most when considering MSC therapy for type 2 diabetes at our clinic in Cancún, México.
No — and any clinic that says otherwise is overstating the evidence. Type 2 diabetes is a chronic, progressive disease driven by insulin resistance and declining β-cell function. Published randomized and meta-analytic data (Zang 2022, Habiba 2024, Kashbour 2025) suggest that MSC therapy may improve glycemic control and reduce insulin requirements in selected patients with T2D, but no high-quality study claims a cure. We do not use that word. MSC therapy at Regeneris in Cancún, México is positioned as an investigational adjunct alongside lifestyle, metformin, GLP-1 / SGLT2 therapy, and insulin where indicated — not as a replacement.
For type 2 diabetes, the most studied route in the published literature is intravenous infusion of mesenchymal stem cells under sterile, physician-supervised conditions — typically umbilical cord-derived (UC-MSC) in the randomized trials. Some study protocols use multiple infusions spaced weeks apart (for example, three infusions at 4-week intervals in the Zang 2022 phase II trial). Your written plan describes exactly which route applies to you and why, with no hidden steps.
Onset is gradual, not immediate. In the published trials, primary endpoints were evaluated at follow-up windows up to 48 weeks; changes in HbA1c and daily insulin dose typically build across multiple months rather than days. We schedule structured follow-up — coordinated with your endocrinologist — to track HbA1c, insulin requirements, and symptoms honestly across that window. If the response is not what you and your physician hoped for, we say so.
In published systematic reviews and randomized trials of MSC therapy in type 2 diabetes (e.g. Zang 2022, Kashbour 2025), no serious adverse events or mortality have been reported during treatment and follow-up across the studies reviewed; the most common events were mild, self-limiting hypoglycemia and minor procedure-related issues. Common risks of any intravenous infusion — transient infusion reaction, low risk of infection — are reviewed with you in your evaluation. Patients with active malignancy, active infection, pregnancy, lactation, or uncontrolled immunosuppression are generally deferred without specialist coordination.
No — and we will not support stopping standard diabetes therapy on your own. Guideline-directed care (lifestyle, metformin, GLP-1 receptor agonists, SGLT2 inhibitors, basal/bolus insulin where indicated) is the foundation of type 2 diabetes management and protects against complications. MSC therapy at Regeneris is investigational and is offered only as an adjunct, co-managed with your endocrinologist. Any reduction in medication is a clinical decision your endocrinologist makes based on objective glycemic data over time, never a unilateral choice driven by a regenerative therapy claim.
Regeneris does not publish prices online for stem cell therapy. Our model is intentional: free medical evaluation first, then a written plan and a personalized quote that reflect your specific case, HbA1c, current medications, and goals. We chose this approach because medicine is not a catalog purchase — a number on a homepage cannot fairly represent the decision you are making about a chronic disease. Your full quote is delivered in writing after evaluation, with no obligation to proceed.
Plain-text question-and-answer pairs in semantic HTML — designed to be easily extracted by AI assistants, search engines, and accessibility tools.
Continue exploring
The full pillar on mesenchymal stem cell therapy at Regeneris: cell sources, mechanism, protocols, and how to start.
ContinueHow COFEPRIS regulates regenerative medicine in México, what donor screening looks like, and how to evaluate any clinic claim.
ContinueTravel, evaluation, and follow-up logistics for cross-border patients coming to our clinic in Cancún, México.
ContinueA 2026 comparison of regulation, available cell types, and travel logistics for cross-border regenerative care.
ContinueSend your goals, recent HbA1c, and endocrinology notes — we'll route your message to a physician for a free medical evaluation.
ContinueThis page is informational and does not constitute medical advice. Mesenchymal stem cell therapy for type 2 diabetes is investigational and is not approved by major regulators for this indication; outcomes vary by patient and protocol, and no individual response is guaranteed. The decision to consider MSC therapy is a medical decision that requires an individualized evaluation with a licensed physician, co-managed with your endocrinologist or primary-care physician; do not stop insulin, metformin, GLP-1 / SGLT2 therapy, or any prescribed medication on your own. Regeneris Therapy operates under COFEPRIS Aviso Sanitario 2323025036X00098 and Aviso de Publicidad 2323022002A00053 in Cancún, México.
Book a free 15-min call with our team.
Send your goals, recent HbA1c, current medications, and any endocrinology notes. A Regeneris physician will review your case from Cancún, México and tell you — honestly — whether MSC therapy is worth considering as an adjunct, what protocol may fit, and what the personalized written quote would look like after your free medical evaluation.